Summary
Labetalol, an alpha-beta-blocker, has been shown to have vasodilating as well as beta-blocking properties. From the theoretical point of view such a drug is likely to be beneficial in the treatment of angina pectoris. There are very few studies investigating the effects of labetalol in normotensive patients with angina pectoris. The three major controlled trials that have been published show that labetalol reduces angina frequency and prolongs exercise duration. In one study the effects of labetalol in anginal subjects using ambulatory monitoring was performed and showed a reduction in silent ischemia as well as a reduction in angina pectoris. Thus labetalol would appear to be an effective antianginal agent. Further studies are necessary to determine if the anti-anginal effect is entirely due to the beta-receptor-blocking activity of the drug or whether labetalol's vasodilating property has important additional benefit.
Similar content being viewed by others
References
Thadani U, Davidson C, Singleton W, Taylor SH. Comparison of five beta-adrenoceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris. Am J Med 1980; 68:243–250.
Hillis LD, Braunwald E. Coronary artery spasm. N Engl J Med 1978; 299:695–702.
Rubio R, Berne RM. Regulation of coronary blood flow. Prog Cardiovas Dis 1975; 18:105–122.
Orlick AE, Ricci DR, Alderman EL, et al. Effects of alpha adrenergic blockade upon coronary haemodynamics. J Clin Invest 1978; 62:459–467.
Mehta J, Feldman RL, Marx JD, Kelly GA. Systematic pulmonary and coronary haemodynamic effects of labetalol in hypertensive subjects. Am J Med 1983; 75:32–39.
Gagon RM, Morissette M, Presant S, et al. Haemodynamic and coronary effects of intravenous labetalol in coronary artery disease. Am J. Cardiol 1982; 49:1267–1269.
Taylor SH, Sutherland GR, Mackenzie GJ, et al. The circulatory effects of intravenous phentolamine in man. Circulation 1965; 31:741–754.
Charness ME, Fishman JA, Robertson D. Exacerbation of angina pectoris by prazosin. South Med J 1979; 72: 1213–1214.
Richards DA. Pharmacological effect of labetalol in man. Br J. Clin Pharmacol 1976; 3:721–723.
Baum T, Sybertz EJ. Pharmacology of labetalol in experimental animals. Am J Med 1983; 75: 15–23.
Opie LH, White D, Lee J, Lubbe WF. Alternatives to beta blockade in therapy of hypertension with angina pectoris: Role of nifedipine or of labetalol. Br J Clin Pharmacol 1982; 13:115–22S.
Frishman WH, Strom JA, Kirschner M, et al. Labetalol therapy in patients with systemic hypertension and angina pectoris: Effects of combined alpha and beta adrenoceptor blockade. Am J Cardiol 1981; 48:917–928.
Upward JW, Akhras F, Jackson G. Oral labetalol in the management of stable angina pectoris in normotensive patients. Br Heart J 1985; 53:53–57.
Quyyumi AA, Wright C, Mockus L, et al. Effects of combined alpha and beta adrenoceptor blockade in patients with angina pectoris. A double blind study comparing labetalol with placebo. Br Heart J 1985; 53:47–52.
Cohn PF. Silent myocardial ischaemia: Dimensions of the problem in patients with and without angina. Am J Med 1986; 80(Suppl 4c):3–8.
Selwyn AP, Fox K, Eves M, et al. Myocardial ischaemia in patients with frequent angina pectoris. Br Med J 1978; 2:1594–1596.
Prida XE, Hill JA, Feldman RL. Systemic and coronary hemodynamic effects of combined alpha and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses. Am J Cardiol 1987; 59:1084–1088.
Brittain RT, Levy GP. A review of the animal pharmacology of labetalol, a combined alpha and beta-adrenoceptor blocking drug. Br J Clin Pharmacol 1976; 3:681–694.
Joyal M, Cremer KF, Pieper JA et al. Systemic, left ventricular and coronary hemodynamic effects of intravenous diltiazem in coronary artery disease. Am J Cardiol 1985; 56:413–417.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fox, K., Quyyumi, A.A. Labetalol in normotensive patients with angina pectoris. Cardiovasc Drug Ther 2, 363–367 (1988). https://doi.org/10.1007/BF00054644
Issue Date:
DOI: https://doi.org/10.1007/BF00054644